SecBot SecBot
6-K ·Filed Nov 5, 2026

HCM

HUTCHMED (China) Ltd
BULLISH
Impact 5/10
Horizonmonths Processed11d 21h ago SEC0001648257-26-000076
Notable filing: 6-K
Actionable Insight ▲ Bullish

Watch for NMPA approval decisions on sovleplenib NDAs in China (primary ITP and wAIHA) and for any initiation of US clinical development for AIHA. The second orphan designation incrementally strengthens the drug's commercial potential but does not change near-term financials.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$14.20
T+0 close · Nov 5, 2026 · via day close
Latest settled
+4.58%
T+5 · $14.85
Vs SPY
+1.29%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $14.20entry
  2. T+1 · 11d ago +6.76%α +6.45% · $15.16
  3. T+5 · 5d ago +4.58%α +1.29% · $14.85
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED announced that the US FDA granted Orphan Drug Designation to sovleplenib for autoimmune hemolytic anemia (AIHA), the second such designation for the drug following one for primary ITP in October 2026. The designation provides eligibility for 7 years of US market exclusivity upon approval, tax credits, fee waivers, and regulatory guidance. NDAs for sovleplenib in primary ITP and warm AIHA are under review in China.

Key Facts

  • US FDA granted Orphan Drug Designation to sovleplenib for AIHA on November 5, 2026.
  • This is the second Orphan Drug Designation for sovleplenib, following one for primary ITP in October 2026.
  • Orphan Drug Designation provides 7 years of US market exclusivity upon FDA approval, tax credits, user fee waivers, and regulatory guidance.
  • NDAs for sovleplenib in primary ITP and warm AIHA are under regulatory review by China's NMPA.
  • HUTCHMED retains all worldwide rights to sovleplenib.

Financial Impact

No financial figures provided; the designation de-risks US regulatory path and extends potential market exclusivity for sovleplenib in a second indication.

future revenueregulatory milestones

Risk Factors

  • Orphan Drug Designation does not guarantee FDA approval; clinical development and regulatory review remain uncertain.
  • No financial terms or market size estimates for AIHA were disclosed.
  • Competing therapies for AIHA may limit commercial uptake even if approved.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000076
Document: hcm-20261105x6k.htm0001648257-26-000076
Document: 0001648257-26-000076-index-headers.html0001648257-26-000076
Document: 0001648257-26-000076-index.html0001648257-26-000076
Document: 0001648257-26-000076.txt0001648257-26-000076
Earnings Context (Synthetic; results releases only)0001648257-26-000076

Track record

33 reports on HCM

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.

Filters
  1. Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
  2. Nov 5, 202611d ago 6-K Bullish 5/10 Viewing Entry $14.20 Now $14.73 +3.73% settles Feb 3
  3. Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
  4. Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
  5. Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
  6. Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
  7. Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
  9. Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
  10. Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
Showing 10 of 33

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026